No kidding, this was completely unexpected. I am v

No kidding, this was completely unexpected. I am very surprised that the company presented this data premarket, and especially that they changed the wording on their boilerplate company description in a way that certainly seemed to indicate the stuff worked.

The only ray of hope is that the study has not gone on long enough to see if LONG-TERM survival is better. If Thermodox kills of mestastases that data will not be reflected in survival for at least another year or two. Company insisted on 12 month trial period according to CEO and obviously they should have gone for a longer trial period. Also, the CONTROL group's survival was 20% higher than expected. That is really surprising because they must have had statistics on expected survival before they started this. Makes you go huh? Glad for the people who lasted longer than expected, but makes you wonder if there is something that they did with the control group that needs to be done with ALL patients -- to explain that longer survival.